Impaired enzymatic defensive activity, mitochondrial dysfunction and proteasome activation are involved in RTT cell oxidative damage-Reference-Cited by-同舟云学术

Impaired enzymatic defensive activity, mitochondrial dysfunction and proteasome activation are involved in RTT cell oxidative damage

Published:2015-10 Issue:10 Volume:1852 Page:2066-2074
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

Cervellati Carlo,Sticozzi Claudia,Romani Arianna,Belmonte Giuseppe,De Rasmo Domenico,Signorile Anna,Cervellati Franco,Milanese Chiara,Mastroberardino Pier Giorgio,Pecorelli Alessandra,Savelli Vinno,Forman Henry J.,Hayek Joussef,Valacchi Giuseppe

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference61 articles.

1. Clinical manifestations and stages of Rett syndrome;Hagberg;Ment. Retard. Dev. Disabil. Res. Rev.,2002

2. The role of MeCP2 in the brain;Guy;Annu. Rev. Cell Dev. Biol.,2011

3. A role for glia in the progression of Rett's syndrome;Lioy;Nature,2011

4. Reversal of neurological defects in a mouse model of Rett syndrome;Guy;Science,2007

5. F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome;De Felice;J. Lipid Res.,2011

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biochemical and molecular determinants of the subclinical inflammatory mechanisms in Rett syndrome;Archives of Biochemistry and Biophysics;2024-07

2. Mitochondrial encephalopathies and myopathies: Our tertiary center's experience;European Journal of Paediatric Neurology;2024-05

3. A proteomic approach to investigate the role of the MECP2 gene mutation in Rett syndrome redox regulatory pathways;Archives of Biochemistry and Biophysics;2024-02

4. RIPK1 activation in Mecp2-deficient microglia promotes inflammation and glutamate release in RTT;Proceedings of the National Academy of Sciences;2024-01-30

5. Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome;Journal of Translational Medicine;2023-10-26